Latin America Liver Disease Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Latin America Liver Disease Treatment Market is segmented By Treatment Type (Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy Drugs), By Disease Type (Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Liver Cancer, Genetic Disorder, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgery Centers, Others) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The Latin America liver disease treatment market reached US$ 1.3 billion in 2023 and is expected to reach US$ 2.02 billion by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031.

The liver disease treatment market is expanding rapidly, driven by the increasing prevalence of liver disorders such as hepatitis, fatty liver disease, and cirrhosis. Factors such as rising alcohol intake, obesity rates, and viral infections all contribute to this trend, creating a greater need for appropriate treatment solutions. The industry offers a wide range of medicines, including antiviral drugs, immunosuppressants, and new gene therapies.
Recent advances in biotechnology and pharmaceuticals have fueled innovation, with many corporations investing in research and development of new medications. This includes medications that target specific pathways involved in liver disease progression, which raises the prospect of more tailored and effective treatments. Furthermore, the growing focus on preventative interventions and early diagnosis is altering market dynamics, with healthcare providers increasingly.

Market Scope

Market Dynamics: Drivers

Increasing prevalence of liver diseases 

The rising prevalence of liver diseases propels the market growth. For instance, according to the National Institute of Health, liver diseases were the eighth leading cause of death in Brazil. The prevalence of hospital admission because of liver disease was 0.72% (853571 hospitalizations), and the mortality rate was 3.34% (308290 deaths). The mean age at hospital admission and death because of liver disease was 48.05 and 58.10 years respectively.

 Both hospitalization and death because of liver disease were more common among men and followed an upward trend over the years. Cirrhosis was the main cause of hospital admissions and death by liver disease in Brazil. The South region of the country had the highest hospital admission rates because of liver disease in Brazil, whereas the Southeast region had the highest mortality rate. In Brazil, there were 57,380 DALYs (30.3 per 100,000 inhabitants) attributable to chronic hepatitis B and cirrhosis due to hepatitis B, with 41,262 DALYs in men. Most burden was caused by YLL (47,015 or 24.8/100,000) rather than YLD (10,365 or 5.5/100,000). 

Chronic hepatitis C and cirrhosis due to hepatitis C were responsible for 207,747 DALYs (109.6/100,000), of which 137,922 were YLL (72.7/100,000) and 69,825 (36.8/100,000) were YLD, with a higher proportion of DALYs in men (73.9%). Cirrhosis due to alcohol or other causes had a total of 536,169 DALYs (1,4% of total DALYs in Brazil), with 418,272 YLL (341,140 in men) and 117,897 YLD (97,965 in men). The highest DALYs rates occurred at ages 60-69 in chronic hepatitis and at ages 45-59 in cirrhosis due to alcohol or other causes.

Restraints

Factors such as high costs associated with the treatment and stringent regulatory requirements for the approval of new treatments are expected to hamper the market. The higher costs of drugs that are associated with the treatment of various liver diseases affect the affordability for many people and this acts as a restraint to the Latin America liver disease treatment market. 

For more details on this report - Request for Sample

Market Segment Analysis

The Latin America liver disease treatment market is segmented based on disease type, treatment type, and end-user.

The segment non-alcoholic fatty liver disease accounted for approximately 42.7% of the Latin America liver disease treatment market share

The non-alcoholic fatty liver disease segment is expected to hold the largest market share over the forecast period. In this segment, the increasing prevalence and recent treatment approvals would drive this market. 

Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat builds up in the liver. This buildup of fat is not caused by heavy alcohol use. When heavy alcohol use causes fat to build up in the liver, this condition is called alcohol-associated liver disease. Two types of NAFLD are nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). People typically develop one type of NAFLD or the other, although sometimes people with one form are later diagnosed with the other form of NAFLD.

For instance, according to the National Institute of Health, in Brazil, a survey was conducted and a total of 1280 patients from 16 Brazilian centers and all five regions were included. The mean age was 49.68 ± 13.59 years; 53.3% were males and 85% were asymptomatic. Hyperlipidemia was observed in 66.8% of cases, obesity in 44.7%, overweight in 44.4%, diabetes in 22.7%, and toxins exposure in 10%. Metabolic syndrome was observed in 41.3% of cases. Elevated levels of ALT, AST, and GGT were observed in 55.8%, 42.2%, and 63.1% cases, respectively. Liver biopsy performed in 437 cases showed: isolated steatosis in 42% cases, steatohepatitis in 58%, and 27% of them also presented fibrosis. Cirrhosis was observed in 15.4% and hepatocellular carcinoma in 0.7%.

Market Segmentation

By Disease Type

• Hepatitis 
• Autoimmune Diseases
• Non-Alcoholic Fatty Liver Disease
• Liver Cancer
• Genetic Disorder
• Others 

By Treatment Type

• Antiviral Drugs  
• Sofosbuvir
• Ombitasvir 
• Immunosuppressants
• Vaccines
• Hepatitis B vaccine
• Hepatitis A vaccine
• Combined hepatitis A and B vaccine 
• Immunoglobulins
• Corticosteroids 
• Prednisone
• Targeted Therapy 
• Sorafenib 
• Regorafenib 
• Chemotherapy Drugs 
• Nivolumab
• Pembrolizumab

By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Market Competitive Landscape

The major global players in the Latin America Pacific liver disease treatment market include Sanofi, Bayer AG, Pfizer Inc., Novartis AG, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., GSK plc., Gilead Sciences Inc., Pharco, Insud Pharma among others.

Key Developments

• In February 2024, Immune-Onc Therapeutics entered into a clinical trial partnership with Roche for a Phase Ib/II clinical trial of IO-108 plus atezolizumab and bevacizumab to treat hepatocellular carcinoma (HCC), the most common type of liver cancer.

Why Purchase the Report?

• To visualize the Latin America liver disease treatment market segmentation based on disease type, treatment type, and end-user as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of Latin America liver disease treatment market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The Latin America liver disease treatment market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies